Tetra Bio Pharma Inc TBPMQ

Tetra Bio-Pharma Inc. is a Canada-based cannabinoid-derived drug discovery and development company. The Company has developed a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. The Company has a pipeline of formulations and drug delivery systems with a portfolio of assets from the early research and development phase to advanced stage clinical programs. Its products include QIXLEEF, CAUMZ, PPP004, REDUVO, and REBORN 1. QIXLEEF is a botanical therapy with a fixed dosage of tetrahydrocannabinol (THC) and cannabidiol (CBD). CAUMZ is its inhaled cannabinoid-derived drug candidate. PPP004 is a topical preparation containing either a standardized amount of CBD or a defined ratio of THC and CBD. REDUVO is a soft gel capsule used to treat chemotherapy-induced nausea and vomiting (CINV) and weight loss and severe nausea in people living with human immunodeficiency virus (HIV) infection. REBORN 1 is in phase II trial.

GREY:TBPMQ - Post by User

Tetra Bio Pharma Inc > Reduvo status?

<< Previous

Bullboard Posts

Next >>

Comment by Golddetectoron Jan 06, 2022 1:23pm

153 Views

Post# 34289769

RE:RE:RE:Reduvo status?

It is short covering time so expect shorts to get more aggressive. That is normal. As for Reduvo it is late already. So Q1 likely as per latest presentation. However, I except Next catalysts to to be QIXLEEF interim, end of reborn enrolment, and start of commercial setup. This is per Tbp December presentation below. Other than that is just shorts hot air.
the link to presentation is below. GL

https://s24.q4cdn.com/136309390/files/doc_presentation/2021/12/Tetra-Bio-Pharma-Corporate-Presentation-December-2021.pdf

<< Previous

Bullboard Posts

Next >>

Anaergia expands relationship with PepsiCo